Ametek vs Emerson Electric
Add, change or remove companies; up to four.
The short version
- Emerson Electric is the larger business, with $18.0B of revenue in fiscal 2025 against $7.4B for Ametek, about 2.4 times as much.
- Ametek grew revenue faster (6.6%, against 3.0%).
- Ametek turned more of its sales into free cash flow (22.6% FCF margin, against 14.8%).
- Ametek earned a higher return on the capital invested in it (13.2%, against 7.6%).
- Investors pay more for each dollar of Emerson Electric’s earnings: a P/E of 35.4x against 35.1x for Ametek.
| Latest fiscal year | AME · FY25 | EMR · FY25 |
|---|---|---|
| Size | ||
| Market cap | $55.2B | $90.7B |
| Revenue | $7.4B | $18.0B |
| Free cash flow | $1.7B | $2.7B |
| Net income | $1.5B | $2.3B |
| Growth | ||
| Revenue growth | 6.6% | 3.0% |
| 5-year growth | 10.3% | 1.4% |
| Share count change | −0.4% | −1.3% |
| Profitability | ||
| Gross margin | 36.0% | 52.8% |
| Operating margin | 25.8% | — |
| Net margin | 20.0% | 12.7% |
| FCF margin | 22.6% | 14.8% |
| Return on capital | 13.2% | 7.6% |
| Return on equity | 14.6% | 10.9% |
| Balance sheet | ||
| Net debt | $1.8B | $11.6B |
| Net debt / EBITDA | 0.8x | 2.5x |
| Dividends and buybacks | $719M | $2.4B |
| Valuation & quality | ||
| P/E | 35.1x | 35.4x |
| Piotroski F-score | 7 | 6 |
Revenue
FY16
AME $3.8B
EMR $14.5B
FY17
AME $4.3B
EMR $15.3B
FY18
AME $4.8B
EMR $17.4B
FY19
AME $5.2B
EMR $18.4B
FY20
AME $4.5B
EMR $16.8B
FY21
AME $5.5B
EMR $12.9B
FY22
AME $6.2B
EMR $13.8B
FY23
AME $6.6B
EMR $15.2B
FY24
AME $6.9B
EMR $17.5B
FY25
AME $7.4B
EMR $18.0B
AME
EMR
Operating margin
FY16
AME 20.6%
EMR —
FY17
AME 21.0%
EMR —
FY18
AME 22.2%
EMR —
FY19
AME 22.8%
EMR —
FY20
AME 22.6%
EMR —
FY21
AME 23.6%
EMR —
FY22
AME 24.4%
EMR —
FY23
AME 25.9%
EMR —
FY24
AME 25.6%
EMR —
FY25
AME 25.8%
EMR —
AME
EMR
Free cash flow
FY16
AME $694M
EMR $2.4B
FY17
AME $758M
EMR $1.4B
FY18
AME $843M
EMR $2.3B
FY19
AME $1.0B
EMR $2.4B
FY20
AME $1.2B
EMR $2.5B
FY21
AME $1.0B
EMR $3.2B
FY22
AME $1.0B
EMR $2.6B
FY23
AME $1.6B
EMR $274M
FY24
AME $1.7B
EMR $2.9B
FY25
AME $1.7B
EMR $2.7B
AME
EMR
Return on capital
FY16
AME 12.1%
EMR 15.5%
FY17
AME 14.8%
EMR 17.0%
FY18
AME 14.0%
EMR 20.7%
FY19
AME 13.5%
EMR 19.8%
FY20
AME 11.3%
EMR 17.0%
FY21
AME 13.1%
EMR 11.4%
FY22
AME 13.1%
EMR 10.4%
FY23
AME 13.2%
EMR 9.4%
FY24
AME 12.8%
EMR 6.0%
FY25
AME 13.2%
EMR 7.6%
AME
EMR
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.